Sep 2026
Neoadjuvant Anlotinib Plus Paclitaxel-Cisplatin for Technically Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Prospective Single-Arm Phase II Study.
BACKGROUND Technically resectable locally advanced head and neck squamous cell carcinoma may require highly morbid surgery. We evaluated short-course neoadjuvant anlotinib plus paclitaxel-cisplatin as a signal-generating strategy. METHODS Twenty-one patients received two 21-day cycles in a prospective, single-arm Pha...
Ran Xu, M.-J. Huang, Zhen-Hua Jiang et al.
· Head and Neck · 0 citations